Nurix raises $250M in registered offering; shares priced at $10.21

Nurix Therapeutics, Inc.

Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.
Proceeds to fund clinical development of bexobrutideg in CLL and autoimmune indications.
New and existing investors participate, including General Atlantic, Redmile, Braidwell, Deep Track, Perceptive Advisors.
Offering expected to close October 23, 2025, subject to customary conditions.
J.P. Morgan, Jefferies, Stifel act as joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.